Commerce Dashboard

Wockhardt Ltd

Go Back

Wockhardt Ltd

  • Multi-ethnic workforce of 8,600 Wockhardt associates from 21 different nationalities globally.
  • 3 research centres and 12 manufacturing plants.
  • Wockhardt is the 4th company in the world to have developed recombinant insulin.
  • First Company in the world, after the originator, to have developed and marketed a long acting insulin analogue, glargine.

Wockhardt is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of pharmaceuticals, biotechnology and a chain of advanced super speciality hospitals.

Wockhardt is a true Indian multi-national company with a multi-ethnic workforce of 8,600 Wockhardt associates from 21 different nationalities globally. It has 3 research centres and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.

Biotechnology has been a significant differentiator and has helped Wockhardt blaze new paths, and set goals that have impacted human life.

The biotechnology programme is geared towards a single objective - making high-quality affordable products that will take the benefits of this amazing science, to a large section of patients.

With very rich experience in mastering biotechnology research, they have built a competent organisation of skilled biotechnologists and ‘concept to market’ capabilities, in all facets of development and manufacture of recombinant biopharmaceuticals.


Wockhardt Ltd: Global pharmaceutical and biotechnology organisation

2013 Wockhardt received the ‘Best Enterprise’ award from the Europe business assembly.
2011 Wockhardt and Shefield bio-science, USA announced a strategic alliance to distribute recombinant insulin in cell culture.
2009 Wockhardt won Government of India patent award.
2007 Wockhardt acquired Morton Grove in the US.
2004 Wockhardt Biotech Park was commissioned.
The biotechnology industry in India comprises >2700 biotech start-ups and is estimated to reach 10,000 by 2024.